Tag Archives: Dendreon
FDA Approves the First Immunotherapy, Provenge, for Metastatic Prostate Cancer
For men with advanced metastatic prostate cancer that did not respond to hormone therapy, there is a new hope for improved survival. FDA has approved an immunotherapy sipuleucel-T (Provenge, Dendreon), for the treatment of asymptomatic or minimally symptomatic metastatic, castration-resistant … Continue reading →
Posted in Cancer, Prostate cancer
|
Tagged Dendreon, immunotherapy, metastatic prostate cancer, Provenge, sipuleucel-T, Survival
|
Comments Off on FDA Approves the First Immunotherapy, Provenge, for Metastatic Prostate Cancer